Patents Assigned to Adherex Technologies, Inc.
-
Patent number: 8658618Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.Type: GrantFiled: October 14, 2010Date of Patent: February 25, 2014Assignee: Adherex Technologies, Inc.Inventor: Thomas Spector
-
Patent number: 8318756Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.Type: GrantFiled: December 5, 2005Date of Patent: November 27, 2012Assignee: Adherex Technologies, Inc.Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
-
Patent number: 7481999Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: December 3, 2004Date of Patent: January 27, 2009Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, Barbara J. Gour, James Matthew Symonds, Stephen Byers
-
Patent number: 7476509Abstract: Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and/or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.Type: GrantFiled: November 14, 2003Date of Patent: January 13, 2009Assignee: Adherex Technologies Inc.Inventors: Orest W Blaschuk, Stephanie D Michaud
-
Patent number: 7456153Abstract: Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.Type: GrantFiled: November 14, 2003Date of Patent: November 25, 2008Assignee: Adherex Technologies Inc.Inventors: Orest W. Blaschuk, Stephanie D. Michaud
-
Patent number: 7446120Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: June 12, 2007Date of Patent: November 4, 2008Assignee: Adherex Technologies, Inc.Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie D. Michaud, Shoameng Wang, Zenjian Hu
-
Patent number: 7268115Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: April 10, 2003Date of Patent: September 11, 2007Assignee: Adherex Technologies, Inc.Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie Denise Michaud, Shaomeng Wang, Zenjian Hu
-
Patent number: 7122623Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: August 1, 2003Date of Patent: October 17, 2006Assignee: Adherex Technologies, Inc.Inventor: Orest W Blaschuk
-
Publication number: 20060183884Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: December 9, 2005Publication date: August 17, 2006Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Barbara Gour, Riaz Farookhi, Anmar Ali, Sarah George
-
Publication number: 20060148753Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.Type: ApplicationFiled: December 5, 2005Publication date: July 6, 2006Applicant: Adherex Technologies, Inc.Inventors: Thomas Spector, William Peters, Donald Kufe, Brian Huber
-
Patent number: 6962969Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: December 3, 2001Date of Patent: November 8, 2005Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20050222037Abstract: Compositions and methods for modulating VE-cadherin-mediated functions are provided. The compositions and methods employ VE-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to a VE-cadherin cell adhesion recognition sequence; (b) a non-peptide mimetic of a VE-cadherin cell adhesion recognition sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a VE-cadherin cell adhesion recognition sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a VE-cadherin cell adhesion recognition sequence or analogue thereof.Type: ApplicationFiled: December 3, 2004Publication date: October 6, 2005Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
-
Publication number: 20050215482Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: ApplicationFiled: December 3, 2004Publication date: September 29, 2005Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
-
Publication number: 20050203025Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: December 3, 2004Publication date: September 15, 2005Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Barbara Gour, James Symonds, Stephen Byers
-
Publication number: 20050163786Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: ApplicationFiled: October 1, 2004Publication date: July 28, 2005Applicant: Adherex Technologies, Inc.Inventors: Patrick Doherty, Orest Blaschuk, Barbara Gour
-
Publication number: 20050129676Abstract: Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.Type: ApplicationFiled: November 14, 2003Publication date: June 16, 2005Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Stephanie Michaud
-
Publication number: 20050037973Abstract: Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used for cancer therapy or to increase immune cell infiltration into tumors. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: ApplicationFiled: July 6, 2004Publication date: February 17, 2005Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, James Symonds, Barbara Gour, J. Alexander
-
Publication number: 20040254099Abstract: Modulating agents for inhibiting &bgr;-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating &bgr;-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.Type: ApplicationFiled: October 14, 2003Publication date: December 16, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, Stephen Byers, Barbara J. Gour
-
Patent number: 6830894Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1999Date of Patent: December 14, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20040248220Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: ApplicationFiled: January 16, 2004Publication date: December 9, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour